Patents by Inventor Nikolaos Papaioannou

Nikolaos Papaioannou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11905285
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: February 20, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20230391773
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 16, 2023
    Publication date: December 7, 2023
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20230339960
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.
    Type: Application
    Filed: June 28, 2023
    Publication date: October 26, 2023
    Inventors: JOHN DAVID TRZUPEK, KATHERINE LIN LEE, MARK EDWARD BUNNAGE, SEUNGIL HAN, DAVID HEPWORTH, FRANK ELDRIDGE LOVERING, JOHN PAUL MATHIAS, NIKOLAOS PAPAIOANNOU, BETSY SUSAN PIERCE, JOSEPH WALTER STROHBACH, STEPHEN WAYNE WRIGHT, CHRISTOPH WOLFGANG ZAPF, LORI KRIM GAVRIN, ARTHUR LEE, DAVID RANDOLPH ANDERSON, KEVIN JOSEPH CURRAN, CHRISTOPH MARTIN DEHNHARDT, EDDINE SAIAH, JOEL ADAM GOLDBERG, XIAOLUN WANG, HORNG-CHIH HUANG, RICHARD VARGAS, MICHAEL DENNIS LOWE, AKSHAY PATNY
  • Plasma Kallikrein inhibitors and uses thereof
    Patent number: 11787796
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 11702424
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: July 18, 2023
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20230167132
    Abstract: The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 16, 2021
    Publication date: June 1, 2023
    Inventors: Suresh Kumar Tipparaju, Jeffrey Scott DePue, Helge Alfred Reisch, Samuel Alexander Stratford, Joseph Stephen Harris, Nikolaos Papaioannou, Sarah Jocelyn Fink
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20230078513
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 16, 2023
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Anti-fibrotic compounds
    Patent number: 11603349
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: March 14, 2023
    Assignee: Certa Therapeutics Pty Ltd
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20220298176
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 11370803
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20220056028
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • Inhibitors of Plasma Kallikrein and uses thereof
    Patent number: 11168083
    Abstract: Provided herein are compounds that inhibit pKal, a serine protease whose activity is responsible for proteolytically cleaving kininogen and generating the potent vasodilator and pro-inflammatory peptide bradykinin, which can lead to painful and debilitating inflammatory attacks (e.g., edema). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating pKal-related diseases and disorders (e.g., edema) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: November 9, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jeremy Travins, Thomas Miller, Nikolaos Papaioannou
  • ANTI-FIBROTIC COMPOUNDS
    Publication number: 20210246100
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Application
    Filed: April 12, 2021
    Publication date: August 12, 2021
    Applicant: Certa Therapeutics Pty Ltd
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • Anti-fibrotic compounds
    Patent number: 11014873
    Abstract: Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 25, 2021
    Assignee: CERTA THERAPEUTICS PTY LTD.
    Inventors: Thomas Miller, Nikolaos Papaioannou
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210079022
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20210078999
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Bicyclic-Fused Heteroaryl or Aryl Compounds
    Publication number: 20200377511
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Applicant: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20200317667
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Bicyclic-fused heteroaryl or aryl compounds
    Patent number: 10793579
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: October 6, 2020
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny